- Home
- MATH vs KZIA Comparison
MATH vs KZIA Comparison
Compare MATH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MATH | KZIA |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | Hong Kong | Australia |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.8M | 74.4M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | MATH | KZIA |
|---|---|---|
| Price | $1.95 | $6.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 48.0K | ★ 286.6K |
| Earning Date | 03-06-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $44,567,257.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.95 | ★ N/A |
| Revenue Growth | ★ 165.86 | N/A |
| 52 Week Low | $1.25 | $2.86 |
| 52 Week High | $4.17 | $17.40 |
Technical Indicators
Market Signals| Indicator | MATH | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 40.60 |
| Support Level | $1.90 | $5.28 |
| Resistance Level | $2.09 | $8.18 |
| Average True Range (ATR) | 0.13 | 0.79 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 9.62 | 28.74 |
Price Performance
Historical ComparisonAbout MATH Metalpha Technology Holding Limited
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.